-
公开(公告)号：JP2004323504A
公开(公告)日：2004-11-18
申请号：JP2003308156
申请日：2003-08-29
申请人： Japan Tobacco Inc , 日本たばこ産業株式会社
发明人： MAEDA KIMIYA , NAGAMORI HIROMASA , NAKAMURA HIROSHI , SHINKAI HISASHI , SUZUKI YASUNORI , TAKAHASHI DAISUKE , TANIGUCHI HISAO
IPC分类号： C07D249/14 , A61K31/195 , A61K31/277 , A61K31/366 , A61K31/4035 , A61K31/41 , A61K31/415 , A61K31/4196 , A61K31/42 , A61K31/421 , A61K31/4245 , A61K31/425 , A61K31/426 , A61K31/433 , A61K31/4402 , A61K31/4406 , A61K31/505 , A61K45/00 , A61P3/06 , A61P9/10 , A61P43/00 , C07C229/46 , C07C255/58 , C07D213/74 , C07D231/38 , C07D239/42 , C07D257/06 , C07D261/14 , C07D263/48 , C07D271/06 , C07D271/10 , C07D275/02 , C07D277/20 , C07D277/42 , C07D285/08 , C07D285/12 , C07D285/135 , C07D405/12
摘要： PROBLEM TO BE SOLVED: To provide a new compound selectively inhibiting the activity of a CETP. SOLUTION: This CETP activity inhibitor is a compound expressed by general formula (1) [wherein, R 1 , R 2 are each a 1-6C alkyl which many be substituted by a halogen atom, or the like; R 3 , R 4 and R 5 are each H, or R 3 and R 4 together with a carbon atom to which R 3 , R 4 bond, may form a homocyclic or heterocyclic ring which may have a substituent; A is N(R 7 )(R 8 ) or the like; ring B is an aryl or a heterocyclic residue; R 6 is H , a halogen, nitro, a 1-6C alkyl or the like; and (n) is 1-3 integer], or its prodrug or pharmaceutically acceptable salt, or includes these compounds. COPYRIGHT: (C)2005,JPO&NCIPI
-
公开(公告)号：JP2013063968A
公开(公告)日：2013-04-11
申请号：JP2012190429
申请日：2012-08-30
申请人： Japan Tobacco Inc , 日本たばこ産業株式会社
发明人： MIURA TOMOYA , IKUKOSHI YOSUKE , KAMIYAMA KAZUTO , MOTODA DAI , IWAYAMA TOSHIHIKO , SUZAWA KOICHI , NAGAMORI HIROMASA , UENO HIROSHI , TAKAHASHI AKIHIKO , SUGIMOTO KAZUYUKI
IPC分类号： C07D401/12 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/4439 , A61K31/495 , A61K31/506 , A61K31/5355 , A61K31/55 , A61P1/10 , A61P3/04 , A61P3/10 , A61P9/00 , A61P9/10 , A61P13/12 , A61P25/00 , A61P27/02 , A61P35/00 , A61P43/00 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12
CPC分类号： C07D403/12 , C07D401/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12
摘要： PROBLEM TO BE SOLVED: To provide a pyrazole compound having SGLT1 inhibitory activities, a pharmaceutical composition containing the same and pharmaceutical use thereof.SOLUTION: This pyrazole compound is expressed by general formula [Ib] or a pharmaceutically acceptable salt thereof.
摘要翻译： 待解决的问题：提供具有SGLT1抑制活性的吡唑化合物，含有该抑制活性的药物组合物及其药物用途。 解决方案：该吡唑化合物由通式[Ib]表示或其药学上可接受的盐。 版权所有（C）2013，JPO＆INPIT
-
公开(公告)号：JP2014185159A
公开(公告)日：2014-10-02
申请号：JP2014105236
申请日：2014-05-21
申请人： Japan Tobacco Inc , 日本たばこ産業株式会社
发明人： MOTOMURA TAKANAO , NAGAMORI HIROMASA , SUZAWA KOICHI , ITO HIROTSUGU , MORITA TORU , KOBAYASHI AKIRA , SHINKAI HISASHI
IPC分类号： C07D231/12 , A61K31/415 , A61P3/10 , A61P9/00 , A61P19/06 , A61P35/00
CPC分类号： C07D205/04 , A61K31/045 , A61K31/05 , A61K31/085 , A61K31/10 , A61K31/121 , A61K31/136 , A61K31/166 , A61K31/167 , A61K31/192 , A61K31/235 , A61K31/277 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/41 , A61K31/415 , A61K31/4155 , A61K31/4196 , A61K31/421 , A61K31/4245 , A61K31/425 , A61K31/435 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/4453 , A61K31/4523 , A61K31/5375 , C07C35/52 , C07C39/42 , C07C43/23 , C07C43/253 , C07C49/83 , C07C59/56 , C07C59/72 , C07C65/17 , C07C69/712 , C07C69/732 , C07C69/76 , C07C215/44 , C07C215/70 , C07C217/20 , C07C233/18 , C07C233/25 , C07C235/42 , C07C235/66 , C07C255/12 , C07C255/53 , C07C259/10 , C07C271/16 , C07C271/30 , C07C311/04 , C07C317/22 , C07C2603/18 , C07D207/04 , C07D211/06 , C07D213/30 , C07D213/56 , C07D231/12 , C07D239/26 , C07D249/08 , C07D257/04 , C07D263/32 , C07D271/06 , C07D271/10 , C07D275/02 , C07D295/08 , C07D295/18 , C07D295/192 , C07D333/22 , C07D401/06 , C07D401/12 , C07D403/12 , C07F7/0818
摘要： PROBLEM TO BE SOLVED: To provide preventive or therapeutic agents for diabetes, diabetic complication, diabetic microangiopathy complication, insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlipidemia, atherosclerotic sclerosis, failure, cardiomyopathy, myocardial ischemia, cerebral ischemia, stroke, pulmonary hypertension, hyperlactacidemia, mitochondrial diseases, mitochondrial encephalomyopathy or cancer, i.e. PDHK inhibitors and the like.SOLUTION: There are provided compounds represented by the general formula [I] or pharmaceutically acceptable salts thereof or solvates thereof. [I], where each symbols are as described in the specification.
摘要翻译： 要解决的问题：提供糖尿病，糖尿病并发症，糖尿病性微血管病并发症，胰岛素抵抗综合征，代谢综合征，高血糖症，高脂血症，动脉粥样硬化硬化症，失败，心肌病，心肌缺血，脑缺血，中风，肺动脉高压， 高通乳液血症，线粒体疾病，线粒体性脑病或癌症，即PDHK抑制剂等。解决方案：提供由通式[I]表示的化合物或其药学上可接受的盐或其溶剂化物。 [I]，其中每个符号如说明书中所述。
-
公开(公告)号：JP2017082005A
公开(公告)日：2017-05-18
申请号：JP2017021326
申请日：2017-02-08
申请人： 日本たばこ産業株式会社 , Japan Tobacco Inc
发明人： MIURA TOMOYA , IKUKOSHI YOSUKE , KAMIYAMA KAZUTO , MOTODA DAI , IWAYAMA TOSHIHIKO , SUZAWA KOICHI , NAGAMORI HIROMASA , UENO HIROSHI , TAKAHASHI AKIHIKO , SUGIMOTO KAZUYUKI
IPC分类号： C07D401/12 , A61K31/4155 , A61K31/4178 , A61K31/422 , A61K31/4439 , A61K31/495 , A61K31/506 , A61K31/5355 , A61K31/55 , A61P1/10 , A61P3/04 , A61P3/10 , A61P9/00 , A61P9/10 , A61P13/12 , A61P25/00 , A61P27/02 , A61P35/00 , A61P43/00 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12
CPC分类号： C07D403/12 , C07D401/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12
摘要： 【課題】SGLT1阻害作用を有するピラゾール化合物、それを含む医薬組成物、及びその医薬用途の提供。【解決手段】下記一般式[Ib]で示される化合物又はその医薬上許容される塩:[式中、各記号は明細書に記載の通りである。]【選択図】なし
-
公开(公告)号：JP2011079801A
公开(公告)日：2011-04-21
申请号：JP2009235687
申请日：2009-10-09
申请人： Japan Tobacco Inc , 日本たばこ産業株式会社
发明人： MOTOMURA TAKANAO , NAGAMORI HIROMASA , SUZAWA KOICHI , ITO HIROTSUGU , MORITA TORU , KOBAYASHI AKIRA , SHINKAI HISASHI
IPC分类号： C07C35/52 , A61K31/045 , A61K31/047 , A61K31/05 , A61K31/085 , A61K31/12 , A61K31/136 , A61K31/165 , A61K31/166 , A61K31/167 , A61K31/18 , A61K31/192 , A61K31/216 , A61K31/235 , A61K31/27 , A61K31/277 , A61K31/381 , A61K31/396 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/4015 , A61K31/402 , A61K31/4025 , A61K31/41 , A61K31/415 , A61K31/4155 , A61K31/4166 , A61K31/421 , A61K31/4245 , A61K31/425 , A61K31/435 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/445 , A61K31/4453 , A61K31/45 , A61K31/4523 , A61K31/454 , A61K31/495 , A61K31/505 , A61K31/506 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61K31/695 , A61P3/00 , A61P3/06 , A61P3/08 , A61P3/10 , A61P3/12 , A61P5/50 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P25/00 , A61P27/02 , A61P27/12 , A61P35/00 , A61P43/00 , C07C39/17 , C07C43/23 , C07C49/83 , C07C59/135 , C07C65/17 , C07C69/712 , C07C69/76 , C07C215/42 , C07C215/70 , C07C217/24 , C07C233/18 , C07C233/25 , C07C235/06 , C07C235/08 , C07C235/12 , C07C235/66 , C07C255/53 , C07C271/16 , C07C311/04 , C07C317/22 , C07D203/18 , C07D205/04 , C07D207/06 , C07D207/14 , C07D207/16 , C07D207/27 , C07D211/22 , C07D211/44 , C07D211/62 , C07D211/76 , C07D213/30 , C07D221/16 , C07D231/12 , C07D233/32 , C07D239/26 , C07D257/04 , C07D263/20 , C07D263/32 , C07D265/10 , C07D265/32 , C07D271/06 , C07D271/10 , C07D275/02 , C07D295/08 , C07D295/18 , C07D295/20 , C07D333/22 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/06 , C07D403/10 , C07D403/12 , C07F7/12
CPC分类号： C07D205/04 , A61K31/045 , A61K31/05 , A61K31/085 , A61K31/10 , A61K31/121 , A61K31/136 , A61K31/166 , A61K31/167 , A61K31/192 , A61K31/235 , A61K31/277 , A61K31/381 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/41 , A61K31/415 , A61K31/4155 , A61K31/4196 , A61K31/421 , A61K31/4245 , A61K31/425 , A61K31/435 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4439 , A61K31/4453 , A61K31/4523 , A61K31/5375 , C07C35/52 , C07C39/42 , C07C43/23 , C07C43/253 , C07C49/83 , C07C59/56 , C07C59/72 , C07C65/17 , C07C69/712 , C07C69/732 , C07C69/76 , C07C215/44 , C07C215/70 , C07C217/20 , C07C233/18 , C07C233/25 , C07C235/42 , C07C235/66 , C07C255/12 , C07C255/53 , C07C259/10 , C07C271/16 , C07C271/30 , C07C311/04 , C07C317/22 , C07C2603/18 , C07D207/04 , C07D211/06 , C07D213/30 , C07D213/56 , C07D231/12 , C07D239/26 , C07D249/08 , C07D257/04 , C07D263/32 , C07D271/06 , C07D271/10 , C07D275/02 , C07D295/08 , C07D295/18 , C07D295/192 , C07D333/22 , C07D401/06 , C07D401/12 , C07D403/12 , C07F7/0818
摘要： PROBLEM TO BE SOLVED: To provide a prophylactic or therapeutic agent for diabetes, diabetic complications, diabetic microangiopathy complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, heart failure, cardiomyopathy, myocardial ischemia, cerebral ischemia, stroke, pulmonary hypertension, hyperlactatemia, mitochondrial disorders, mitochondrial encephalomyopathy or cancer, i.e., a PDHK inhibitor or the like. SOLUTION: There is specifically disclosed a compound represented by general formula [I], a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable salt. In the formula, R a is (1) a hydrogen atom, or (2) a halogen atom; R b is (1) a hydrogen atom, (2) a halogen atom, (3) a 1-6C alkyl group, (4) a 2-6C alkenyl group or the like; R c is (1) a hydrogen atom, (2) a halogen atom, (3) a 1-6C alkyl group, (4)-C(=O)-OR c1 (in the formula, R c1 shows a hydrogen atom or a 1-6C alkyl group) or the like; X d is (1) a nitrogen atom or (2) C-R d [in the formula, R d is (i) a hydrogen atom, (ii) a halogen atom, (iii) a 1-6C alkyl group, (iv) a 2-6C alkenyl group] or the like; R e is the same or different, (1) a halogen atom or (2) a 1-6C alkyl group; and n is 0 or an integer of 1-3. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译： 要解决的问题：提供糖尿病，糖尿病并发症，糖尿病性微血管病并发症，胰岛素抵抗综合征，代谢综合征，高血糖症，血脂异常，动脉粥样硬化，心力衰竭，心肌病，心肌缺血，脑缺血，中风的预防或治疗剂 ，肺动脉高压，高乳酸症，线粒体疾病，线粒体性脑病或癌症，即PDHK抑制剂等。 解决方案：具体公开了通式[I]表示的化合物，化合物的药学上可接受的盐或化合物的溶剂化物或其药学上可接受的盐。 在该式中，R“SP”a 是（1）氢原子，或（2）卤素原子; （1）氢原子，（2）卤素原子，（3）1-6C烷基，（4）2-6C烯基等; （1）氢原子，（2）卤素原子，（3）1-6C烷基，（4）-C（= O）-OR
c1 < / SP>（式中，R c1 表示氢原子或1-6C烷基）等; （1）氮原子或（2）CR（d）在式中，R（SP）d 是（i）氢原子 ，（ⅱ）卤素原子，（ⅲ）1-6C烷基，（ⅳ）2-6C烯基]等; R 1相同或不同，（1）卤素原子或（2）1-6C烷基; n为0或1-3的整数。 版权所有（C）2011，JPO＆INPIT
-
-
-
-
搜索结果
5 条记录 (耗时 0.041 秒)
